Group 1 - The core viewpoint presented by the Hong Kong Stock Exchange's Chief China Economist, Ba Shusong, is that the traditional economic growth model is no longer sustainable, leading to a shift in asset allocation logic [1] - Ba Shusong anticipates a slowdown in global economic growth and a continuous decline in traditional asset returns, making it increasingly difficult for investors to achieve their return objectives solely through beta returns [1] - There is a rising trend in the proportion of actively managed funds globally, indicating that investors are increasingly pursuing alpha returns in the new market environment, particularly evident in the alternative asset sector [1]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) is actively advancing initiatives to enhance connectivity with mainland exchanges, including integrating block trading into the mutual market access mechanism and allowing RMB counter trading in Hong Kong stocks [1] Group 1 - The 2025 HKEX China Opportunities Forum was held in Shanghai on October 22 [1] - HKEX Group CEO Charles Li emphasized ongoing efforts to improve trading mechanisms and connectivity with mainland exchanges [1] - Initiatives include the inclusion of block trading in the mutual access framework and the introduction of RMB counter trading for Hong Kong stocks [1]

Core Insights - Hong Kong has become the third largest ETP market globally, surpassing South Korea and Japan, with a total asset management scale of HKD 653.5 billion, reflecting a year-on-year growth of 34.1% [1][2] - The average daily trading volume of ETPs reached HKD 37.8 billion by the end of September, marking a significant increase of 146% year-on-year, driven primarily by the popularity of technology-focused ETFs and cross-border trading through the Stock Connect programs [1][2] Group 1 - The ETP market in Hong Kong is experiencing explosive growth, with technology-related ETFs, particularly the flagship Hang Seng Tech Index ETP, significantly contributing to overall market expansion [1] - The average daily trading volume of ETFs through the Stock Connect programs reached HKD 4.2 billion and RMB 3.2 billion respectively, with a record high of HKD 9.1 billion in August [2] - A total of 290 eligible ETFs are available for trading through the Stock Connect, with expectations for more ETFs to be included in November, indicating a sustained increase in cross-border ETF trading activity [2]

Core Viewpoint - CICC has raised its profit forecast for Hong Kong Exchanges and Clearing (HKEX) for 2025 by 3% to HKD 17.1 billion, while maintaining the 2026 forecast largely unchanged. The current trading multiples are at 31x for both 2025 and 2026 P/E, with a target price of HKD 500, indicating an 18% upside potential [1]. Group 1 - The forecast for Q3 2025 indicates a year-on-year profit increase of 49% and a quarter-on-quarter increase of 5% [2]. - CICC expects Q3 revenue to rise by 40% year-on-year and 4% quarter-on-quarter to HKD 75.3 billion, with core fee income projected to increase by 57% year-on-year and 18% quarter-on-quarter to HKD 65.1 billion [2]. - CICC anticipates total revenue and profit for the first three quarters of 2025 to increase by 35% and 42% year-on-year, reaching HKD 216.1 billion and HKD 132.0 billion, respectively [2]. Group 2 - Trading activity remains robust, with Q3 average daily turnover (ADT) expected to rise by 141% year-on-year and 20% quarter-on-quarter to HKD 286.4 billion [2]. - Southbound ADT is projected to increase by 285% year-on-year and 36% quarter-on-quarter to HKD 152.5 billion, accounting for 26.6% of Hong Kong stocks [2]. - The number of IPOs in Q3 is expected to reach 25, raising HKD 73.5 billion, which is a 74% year-on-year increase but a 19% quarter-on-quarter decrease [2]. Group 3 - Investment income is expected to decline by 18% year-on-year and 36% quarter-on-quarter to HKD 9.9 billion in Q3 2025 [3]. - The narrowing of margin interest spreads is anticipated due to a decline in long-term yields and a rise in short-term borrowing costs, which may negatively impact investment income [3]. - Market volatility is expected to decrease, leading to a reduction in margin requirements for derivatives trading, further affecting investment income performance [3]. Group 4 - The fundamental outlook for HKEX remains strong, with high trading activity supported by a favorable liquidity environment for foreign capital [4]. - The average daily turnover for Hong Kong stocks reached HKD 288 billion in October, indicating sustained high trading activity [4]. - CICC suggests that the anticipated easing of monetary policy by the Federal Reserve could support liquidity in the Hong Kong market, presenting potential investment opportunities [4].

智通财经APP获悉，中金发布研报称，考虑市场成交活跃度提振，上调香港交易所(00388)25e盈利预测 3%至171亿港币、维持26e预测基本不变。公司当前交易于31x/31x 25e/26e P/E，维持跑赢行业及目标价 500港币不变(37x/37x 25e/26e P/E及18%上行空间)。 中金主要观点如下： 预测3Q25盈利同比+49%/环比+5% 1)现货：3Q ADT同比+141%/环比+20%至2,864亿港币，其中南下ADT同比+285%/环比+36%至1,525亿 港币、占港股26.6%，北上ADT同比+144%/环比+77%至2,687亿元、占A股7.1%;2)衍生品：衍生品ADV 整体同比+12%/环比+7%至165万张，其中股指ADV同比-7%/环比-6%至72.9万张，个股期权ADV同比 +33%/环比+19%至92.0万张;3)商品：LME ADV同比+3%/环比-9%至70.5万张;4)上市：3Q完成IPO 25 家、融资额735亿港币(同比+74%/环比-19%)。 港交所计划于11月5日披露3Q25业绩：该行预计3Q收入同比+40%/环比+4%至75.3亿港币，剔除投资收 ...

高盛发布研报称，基于香港交易所(00388)9月及10月至今的成交量数据，调整2025至27年每股盈利预 测，分别上调0.8%、下调0.5%及上调0.1%，并引入2028年每股盈测为15.4港元;维持"买入"评级及目标 价544港元。 ...

Core Viewpoint - The Hong Kong Stock Exchange's senior advisor, Apurv Bagri, emphasizes the urgent need for the London Metal Exchange (LME) and its users to adopt "disturbing" measures for modernization to ensure long-term profitability [1] Group 1: Modernization Needs - The modernization of the LME is deemed crucial for its long-term future [1] - Users of the LME are encouraged to consider "controversial" measures to maintain profitability [1] Group 2: Strategic Recommendations - The LME should actively explore cross-listing contracts on other exchanges to enhance market liquidity and accessibility [1] - There is a need for the LME to further expand its international business footprint [1]

Core Viewpoint - Hong Kong Stock Exchange (HKEX) is set to launch the Hang Seng Biotechnology Index Futures on November 28, 2025, aiming to enhance its derivatives product ecosystem and provide investors with effective risk management tools in the rapidly growing biotechnology sector [1][1]. Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index, focusing on one of the fastest-growing and most dynamic sectors [1]. - The launch is contingent upon regulatory approval, indicating a structured approach to introducing new financial products [1]. Group 2: Market Context - The biotechnology industry is currently one of the hottest sectors in the capital markets, driven by technological innovation and significant global healthcare demand [1]. - Since the introduction of the listing regime reform in 2018, the biotechnology and healthcare sectors have become the fastest-growing industries on the Hong Kong capital market, with over 260 biotechnology and healthcare companies listed, totaling a market capitalization of over HKD 4.8 trillion, which is four times the approximately HKD 1.2 trillion at the end of 2018 [1][1].

智通财经APP获悉，港交所(00388)再跌超3%，截至发稿，跌3%，报419.8港元，成交额44.54亿港元。 消息面上，上周五贸易战升级态势超出市场，投资者风险偏好下降带动港股估值回调。华泰证券表示， 短期操作方向判断的关键在于市场情绪是否已经较为极致，从资金面和港股情绪指标看还有进一步释放 空间，贸易摩擦问题未来一两周演进路径方差较大，高波动行情或仍将持续。 值得注意的是，港交所将于11月5日公布第三季度业绩。瑞银预测季度收入及纯利将同比增长43%及 53%，达到77亿及48亿元，再创新高。该行预测较市场普遍预期高出8%及11%。考虑到市场气氛情况及 南下资金参与度上升，瑞银将港交所2025至2027年日均成交额预测上调9%至16%，并将港交所每股盈 利预测上调7%至12%，目标价485港元，评级"中性"。 ...

Core Viewpoint - Hong Kong Stock Exchange plans to launch the Hang Seng Biotechnology Index futures on November 28, 2025, providing investors with precise risk management tools in a rapidly growing sector [1] Group 1: Product Launch - The new futures contract will be based on the Hang Seng Biotechnology Index, which tracks the performance of the 30 largest biotechnology, pharmaceutical, and medical device companies listed in Hong Kong that are eligible for Stock Connect trading [1] - The introduction of this futures product aims to enhance investment channels in the biotechnology sector and provide effective hedging tools [1] Group 2: Market Context - The biotechnology industry is currently one of the hottest sectors in the capital markets, driven by technological innovation and global healthcare demand [1] - Since the listing reform in 2018, the biotechnology and healthcare sectors have become some of the fastest-growing industries in Hong Kong's capital market [1] Group 3: Market Statistics - There are currently over 260 biotechnology and healthcare companies listed on the Hong Kong Stock Exchange, with a total market capitalization exceeding HKD 4.8 trillion, which is four times the approximately HKD 1.2 trillion at the end of 2018 [1]